Histone Deacetylase Inhibitors Market Report 2026

The histone deacetylase inhibitors market size has grown strongly in recent years. It will grow from $1.29 billion in 2025 to $1.39 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to early success of hdac inhibitors in hematological malignancies, growing understanding of epigenetic regulation in disease, availability of approved first-generation hdac inhibitors, expansion of cancer research infrastructure, increased investment in targeted cancer therapies.

The histone deacetylase inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.81 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising global cancer incidence, growing pipeline of epigenetic-based therapies, increasing focus on precision oncology approaches, expansion of clinical trials for neurological and inflammatory indications, demand for more selective and safer epigenetic drugs. Major trends in the forecast period include increasing use of hdac inhibitors in oncology treatment regimens, growing focus on selective and isoform-specific hdac inhibitors, rising adoption of combination therapies involving hdac inhibitors, expansion of hdac inhibitor research beyond cancer indications, steady growth in oral hdac inhibitor formulations.

The rising incidence of cancer is expected to drive the growth of the histone deacetylase inhibitors market in the coming years. The increasing occurrence of cancer is mainly attributed to aging populations, greater exposure to risk factors such as tobacco use, dietary habits, and environmental pollutants, as well as improved diagnostic methods that enable earlier and more frequent detection. Histone deacetylase inhibitors are used in cancer treatment by modifying chromatin structure, which activates tumor suppressor genes and suppresses oncogenes, thereby triggering cell cycle arrest and apoptosis in cancer cells. For example, in February 2024, according to the World Health Organization, a US-based intergovernmental organization, around 35 million new cancer cases are projected by 2050, representing a 77% increase compared to the estimated 20 million cases reported in 2022. Hence, the growing incidence of cancer is fueling the expansion of the histone deacetylase inhibitors market.

Major companies operating in the histone deacetylase inhibitors market are emphasizing the development of innovative product formulations, such as oral histone deacetylase (HDAC) inhibitors, to broaden treatment options and enhance patient convenience and adherence. An oral histone deacetylase inhibitor is a medication administered by mouth that targets HDAC enzymes involved in gene regulation and may be used to treat various conditions, including cancer and inflammatory diseases. For instance, in March 2024, Italfarmaco S.p.A., an Italy-based pharmaceutical company, received approval from the Food and Drug Administration for Duvyzat (givinostat), an oral histone deacetylase inhibitor, for treating Duchenne muscular dystrophy (DMD) in patients aged six years and older. Duvyzat works by mitigating the cascade of events that lead to muscle damage, potentially slowing the progression of muscle degeneration associated with DMD. By inhibiting excessive HDAC activity, it helps reduce inflammation and fibrosis while supporting muscle fiber regeneration. The approval was based on results from the pivotal phase 3 EPIDYS trial, which achieved its primary endpoint by showing a statistically significant reduction in the time required to complete the four-stair climb test compared to placebo.

In January 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Mirati Therapeutics Inc. for an undisclosed amount. This acquisition is intended to strengthen and diversify Bristol Myers Squibb’s oncology portfolio, which includes the commercial lung cancer drug KRAZATI (adagrasib) and a robust KRAS-focused development program with two Phase 1 candidates. The move aims to accelerate the development and delivery of innovative cancer therapies and support the company’s long-term growth in oncology. Mirati Therapeutics Inc. is a US-based targeted oncology company focused on developing cancer treatments, including histone deacetylase inhibitors.

Major companies operating in the histone deacetylase inhibitors market are Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Shenzhen Chipscreen Biosciences Co. Ltd., Celgene Corporation, Spectrum Pharmaceuticals Inc., Curis Inc., Onxeo SA, Celleron Therapeutics, Forum Pharmaceuticals Inc., Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Karyopharm Therapeutics Inc., Medivir AB, Huya Bioscience International LLC, Crystal Genomics Inc., Midatech Pharma PLC, Regenacy Pharmaceuticals Inc.

North America was the largest region in the histone deacetylase inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the histone deacetylase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the histone deacetylase inhibitors market by increasing the cost of imported active pharmaceutical ingredients, chemical intermediates, and specialized laboratory equipment used in drug development and manufacturing. These impacts have been most evident in oncology-focused HDAC inhibitor segments, particularly in North America and Europe where complex synthesis often relies on global supply chains. Asia-Pacific manufacturers have experienced cost fluctuations due to trade dependencies. However, tariffs have encouraged localized synthesis capabilities and domestic manufacturing investments, supporting long-term supply chain resilience.

The histone deacetylase inhibitors market research report is one of a series of new reports that provides histone deacetylase inhibitors market statistics, including histone deacetylase inhibitors industry global market size, regional shares, competitors with a histone deacetylase inhibitors market share, detailed histone deacetylase inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the histone deacetylase inhibitors industry. This histone deacetylase inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Histone deacetylase inhibitors are a category of compounds that block the activity of histone deacetylases, which are enzymes responsible for removing acetyl groups from histone proteins. By inhibiting these enzymes, histone acetylation levels increase, resulting in a more relaxed chromatin structure and changes in gene expression.

The main classification types of histone deacetylase inhibitors include Class I histone deacetylases (HDACs), Class II histone deacetylases (HDACs), Class III histone deacetylases (HDACs), and others. Histone deacetylases are a group of enzymes that remove acetyl groups from histone proteins, causing chromatin to condense and suppress gene transcription. These inhibitors can be administered through oral and injectable routes and are distributed via hospital pharmacies, online pharmacies, retail pharmacies, and other channels. They are used across various applications, including oncology, neurology, and others, with end users such as hospitals, home care settings, specialty clinics, and others.

The histone deacetylase inhibitors market consists of sales of bioinformatics tools, cell culture systems, laboratory equipment, and diagnostic devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.